Curative Biotechnology Financials
| CUBT Stock | USD 0.01 0.0001 1.16% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.0999 | 0.1052 |
|
|
Investors should never underestimate Curative Biotechnology's ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Curative Biotechnology's cash flow, debt, and profitability to make informed and accurate decisions about investing in Curative Biotechnology.
Net Income |
|
Curative | Select Account or Indicator |
Understanding current and past Curative Biotechnology Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Curative Biotechnology's financial statements are interrelated, with each one affecting the others. For example, an increase in Curative Biotechnology's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Curative Biotechnology's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Curative Biotechnology. Check Curative Biotechnology's Beneish M Score to see the likelihood of Curative Biotechnology's management manipulating its earnings.
Curative Biotechnology Stock Summary
Curative Biotechnology competes with Eliem Therapeutics, Scpharmaceuticals, Milestone Pharmaceuticals, Seres Therapeutics, and Lumos Pharma. Curative Biotechnology, Inc. operates as a development-stage biomedical company. Curative Biotechnology, Inc. was founded in 1995 and is headquartered in Boca Raton, Florida. Curative Biotechnology operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NYSE MKT Exchange |
| Business Address | 3801 PGA Blvd, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | curativebiotech.com |
| Phone | 561 907 8990 |
| Currency | USD - US Dollar |
Curative Biotechnology Key Financial Ratios
| Return On Equity | -3.98 | ||||
| Price To Sales | 158.53 X | ||||
| Revenue | 132.32 K | ||||
| Gross Profit | 100.21 K | ||||
| EBITDA | (2.5 M) |
Curative Biotechnology Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Retained Earnings | (3.7M) | (8.1M) | (26.9M) | (32.6M) | (38.2M) | (36.3M) | |
| Total Assets | 39.8K | 2.3M | 2.4M | 2.1M | 2.6M | 1.3M | |
| Other Current Liab | 535.6K | (124.8) | 105.1K | 729.6K | (17.2K) | 0.0 | |
| Net Debt | 124.8 | 399.2K | (670.3K) | 1.0M | 2.2M | 2.3M | |
| Total Liab | 397.1K | 6.8M | 18.8M | 22.6M | 5.7M | 7.8M | |
| Short Term Debt | 198.8K | 124.8 | 559.8K | 1.1M | 2.3M | 2.4M | |
| Net Invested Capital | (360.8K) | (4.0M) | (16.4M) | (19.5M) | (17.5M) | (16.6M) | |
| Net Working Capital | (397.1K) | 1.5M | 23.6K | (4.4M) | (4.0M) | (3.8M) |
Curative Biotechnology Key Income Statement Accounts
The reason investors look at the income statement is to determine what Curative Biotechnology's earnings per share (EPS) will be in order to see if they want to buy more shares or not. For example, if a company earned $20 million in the last quarter and has 100,000 shares outstanding, its EPS is 20 cents. If you find that this number beats analysts' forecasts or is higher than it was from the same period last year, then you might want to buy more of this stock even though its price per share may not have changed.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Income Before Tax | 332.0K | (4.7M) | (5.3M) | (5.6M) | (4.0M) | (3.8M) | |
| Net Income | 332.0K | (4.7M) | (5.3M) | (5.6M) | (5.8M) | (5.5M) |
Curative Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Curative Biotechnology's current stock value. Our valuation model uses many indicators to compare Curative Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Curative Biotechnology competition to find correlations between indicators driving Curative Biotechnology's intrinsic value. More Info.Curative Biotechnology is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . At this time, Curative Biotechnology's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Curative Biotechnology by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Curative Biotechnology Systematic Risk
Curative Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Curative Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Curative Biotechnology correlated with the market. If Beta is less than 0 Curative Biotechnology generally moves in the opposite direction as compared to the market. If Curative Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Curative Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Curative Biotechnology is generally in the same direction as the market. If Beta > 1 Curative Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Steps to analyze company Financials for Investing
There are several different ways that investors can use financial statements to try and predict whether a stock price will go up or down. Unfortunately, there is no surefire formula, but there are some general guidelines you should consider when looking at the numbers. First, realize what kind of company it is so you know if its revenues are more likely to grow or shrink over time. For example, a software company's revenue is expected to increase yearly due to new products and services that its customers will want to buy. At the same time, a car manufacturer might not be able to sell as many cars when the economy slows down, so it would have less net income during those times. Second, pay attention to its debt-to-equity ratio because this number will tell you how much risk it has. If a company such as Curative Biotechnology is not taking on any additional risks, its debt-to-equity should be less than one. As a general rule of thumb, if the market value or book value (which can be found in the footnotes) of assets exceeds the company's liabilities, then it is probably in good shape. Finally, use other financial statements to determine if a stock price will go up or down because investors are always looking for growth opportunities when they buy new stocks. For example, if you see that the net revenue of Curative has grown by more than 25% over the last five years, then there is a good chance that it will continue growing by at least 20% or more each year. On the other hand, if you see that net revenue has only increased by about 15%, which is barely above inflation levels, then chances are it will not grow much faster than this over time, and investors may shy away from buying it. In summary, you can determine if Curative Biotechnology's financials are consistent with your investment objective using the following steps:- Review Curative Biotechnology's balance sheet accounts, such as liabilities and equity, to understand its overall financial position.
- Analyze the income statement and examine the company's revenue, expenses, and profits over time to determine its financial performance.
- Study the cash flow inflows and outflows to understand Curative Biotechnology's liquidity and solvency.
- Look at the growth rates in revenue, earnings, and cash flow over time to determine its potential for future growth.
- Compare Curative Biotechnology's financials to those of its peers to see how it stacks up and identify any potential red flags.
- Use valuation ratios to evaluate the company's financials using commonly used ratios such as the price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and enterprise value-to-earnings before interest, taxes, depreciation, and amortization (EV/EBITDA) ratio to determine if Curative Biotechnology's stock is overvalued or undervalued.
Today, most investors in Curative Biotechnology Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Curative Biotechnology's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Curative Biotechnology growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Curative Biotechnology November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Curative Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Curative Biotechnology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Curative Biotechnology based on widely used predictive technical indicators. In general, we focus on analyzing Curative Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Curative Biotechnology's daily price indicators and compare them against related drivers.
| Downside Deviation | 14.78 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 79.53 | |||
| Value At Risk | (20.45) | |||
| Potential Upside | 25.0 |
Additional Tools for Curative Stock Analysis
When running Curative Biotechnology's price analysis, check to measure Curative Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biotechnology is operating at the current time. Most of Curative Biotechnology's value examination focuses on studying past and present price action to predict the probability of Curative Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biotechnology's price. Additionally, you may evaluate how the addition of Curative Biotechnology to your portfolios can decrease your overall portfolio volatility.